CN116751179A - 一种从桑白皮中分离的新化合物及其制备方法和应用 - Google Patents
一种从桑白皮中分离的新化合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN116751179A CN116751179A CN202310764253.5A CN202310764253A CN116751179A CN 116751179 A CN116751179 A CN 116751179A CN 202310764253 A CN202310764253 A CN 202310764253A CN 116751179 A CN116751179 A CN 116751179A
- Authority
- CN
- China
- Prior art keywords
- extract
- silica gel
- methanol
- reduced pressure
- under reduced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 240000000249 Morus alba Species 0.000 title claims description 14
- 235000008708 Morus alba Nutrition 0.000 title claims description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 84
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000000284 extract Substances 0.000 claims abstract description 30
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000000741 silica gel Substances 0.000 claims abstract description 21
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 14
- 238000001914 filtration Methods 0.000 claims abstract description 13
- 239000002904 solvent Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000012528 membrane Substances 0.000 claims abstract description 8
- 238000010992 reflux Methods 0.000 claims abstract description 8
- 238000010898 silica gel chromatography Methods 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 238000010828 elution Methods 0.000 claims abstract description 6
- 239000000706 filtrate Substances 0.000 claims abstract description 6
- 238000011068 loading method Methods 0.000 claims abstract description 6
- 239000000126 substance Substances 0.000 claims abstract description 5
- 238000002156 mixing Methods 0.000 claims abstract description 3
- 239000002024 ethyl acetate extract Substances 0.000 claims description 12
- 229930182733 sanggenol Natural products 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 8
- 239000000945 filler Substances 0.000 claims description 7
- 208000032612 Glial tumor Diseases 0.000 claims description 6
- 206010018338 Glioma Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 5
- 238000007664 blowing Methods 0.000 claims description 5
- 210000000481 breast Anatomy 0.000 claims description 5
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 claims description 5
- 239000003480 eluent Substances 0.000 claims description 5
- 201000002313 intestinal cancer Diseases 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 238000004811 liquid chromatography Methods 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 238000004007 reversed phase HPLC Methods 0.000 claims description 5
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 5
- 238000004809 thin layer chromatography Methods 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 claims description 4
- 150000001450 anions Chemical class 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 150000002500 ions Chemical class 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 238000004366 reverse phase liquid chromatography Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 1
- 238000003756 stirring Methods 0.000 abstract description 7
- 238000007605 air drying Methods 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 21
- 239000000243 solution Substances 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- AFOKZNPZDXHDHD-UHFFFAOYSA-N Morusinol Chemical compound O1C2=C3C=CC(C)(C)OC3=CC(O)=C2C(=O)C(CCC(C)(O)C)=C1C1=CC=C(O)C=C1O AFOKZNPZDXHDHD-UHFFFAOYSA-N 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- HDHRTQZSBFUBMJ-UHFFFAOYSA-N Artonin E Natural products O1C2=C3C=CC(C)(C)OC3=CC(O)=C2C(=O)C(CC=C(C)C)=C1C1=CC(O)=C(O)C=C1O HDHRTQZSBFUBMJ-UHFFFAOYSA-N 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- XFFOMNJIDRDDLQ-UHFFFAOYSA-N morusin Chemical compound O1C2=C3C=CC(C)(C)OC3=CC(O)=C2C(=O)C(CC=C(C)C)=C1C1=CC=C(O)C=C1O XFFOMNJIDRDDLQ-UHFFFAOYSA-N 0.000 description 3
- WUBUWBUVAKMGCO-UHFFFAOYSA-N morusin Natural products CC(=CCC1=C(Cc2c3C=CC(C)(C)Oc3cc(O)c2C1=O)c4ccc(O)cc4O)C WUBUWBUVAKMGCO-UHFFFAOYSA-N 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- KEIIIPKLVSSAEI-UHFFFAOYSA-N Albanin A Chemical compound O1C2=CC(O)=CC(O)=C2C(=O)C(CC=C(C)C)=C1C1=CC=C(O)C=C1O KEIIIPKLVSSAEI-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- YIHMXHFAOIEYBW-BHNQILPDSA-N Kuwanon O Chemical compound CC1=C[C@@H]([C@H]([C@@H](C1)C2=C(C=C(C=C2)O)O)C(=O)C3=C(C(=C(C=C3)O)CC=C(C)C)O)C4=C(C=CC(=C4O)[C@@H]5CC(=O)C6=C(C=C(C=C6O5)O)O)O YIHMXHFAOIEYBW-BHNQILPDSA-N 0.000 description 2
- LHPRYOJTASOZGJ-UHFFFAOYSA-N Moracin M Chemical compound O1C2=CC(O)=CC=C2C=C1C1=CC(O)=CC(O)=C1 LHPRYOJTASOZGJ-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- -1 coumarin, stilbenes Chemical class 0.000 description 2
- MUUDYSFWQUSAOO-UHFFFAOYSA-N cudraflavone C Chemical compound CC(C)=CCC=1C(=O)C2=C(O)C(CC=C(C)C)=C(O)C=C2OC=1C1=CC=C(O)C=C1O MUUDYSFWQUSAOO-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000009982 effect on human Effects 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 2
- 230000005918 in vitro anti-tumor Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- FEAIYAOTVUYWQZ-AIQWNVMPSA-N 2-[3-[(1s,5r,6s)-6-(2,4-dihydroxybenzoyl)-5-(2,4-dihydroxyphenyl)-3-methylcyclohex-2-en-1-yl]-2,4-dihydroxyphenyl]-5,7-dihydroxy-3-(3-methylbut-2-enyl)chromen-4-one Chemical compound O=C([C@H]1[C@@H](CC(C)=C[C@@H]1C=1C(O)=CC=C(C=1O)C1=C(C(C2=C(O)C=C(O)C=C2O1)=O)CC=C(C)C)C=1C(=CC(O)=CC=1)O)C1=CC=C(O)C=C1O FEAIYAOTVUYWQZ-AIQWNVMPSA-N 0.000 description 1
- HRCGUZAOTZXLFY-UHFFFAOYSA-N 3,5-dihydroxybenzaldehyde Chemical compound OC1=CC(O)=CC(C=O)=C1.OC1=CC(O)=CC(C=O)=C1 HRCGUZAOTZXLFY-UHFFFAOYSA-N 0.000 description 1
- HMTMYIWMPJSCAZ-GOSISDBHSA-N 5-[(6r)-6-(2-hydroxypropan-2-yl)-5,6-dihydrofuro[3,2-f][1]benzofuran-2-yl]benzene-1,3-diol Chemical compound C([C@@H](OC1=CC=2O3)C(C)(O)C)C1=CC=2C=C3C1=CC(O)=CC(O)=C1 HMTMYIWMPJSCAZ-GOSISDBHSA-N 0.000 description 1
- QFUCSEIKNTUPPA-GOSISDBHSA-N 5-[(6r)-6-hydroxy-7,7-dimethyl-5,6-dihydrofuro[3,2-g]chromen-2-yl]benzene-1,3-diol Chemical compound CC([C@@H](CC1=CC=2C=3)O)(C)OC1=CC=2OC=3C1=CC(O)=CC(O)=C1 QFUCSEIKNTUPPA-GOSISDBHSA-N 0.000 description 1
- MJJWBJFYYRAYKU-WPFUYSAKSA-N Albanol A Natural products Oc1c([C@@]23Oc4c(c(O)cc(-c5oc6c(c5)ccc(O)c6)c4)[C@H]4[C@H]2[C@@H](c2c(O3)cc(O)cc2)CC(C)=C4)ccc(O)c1 MJJWBJFYYRAYKU-WPFUYSAKSA-N 0.000 description 1
- SMHBZVSVLIBGGO-UUWRZZSWSA-N Albanol B Natural products C1([C@]23OC4=CC(O)=CC=C4C=4C=C(C=C(C5=C(O)C=C(C=C5O3)C=3OC5=CC(O)=CC=C5C=3)C=42)C)=CC=C(O)C=C1O SMHBZVSVLIBGGO-UUWRZZSWSA-N 0.000 description 1
- SMHBZVSVLIBGGO-UHFFFAOYSA-N Albanol B Chemical compound O1C2=CC(C=3OC4=CC(O)=CC=C4C=3)=CC(O)=C2C(C=23)=CC(C)=CC=2C2=CC=C(O)C=C2OC31C1=CC=C(O)C=C1O SMHBZVSVLIBGGO-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- DKBPTKFKCCNXNH-YWUCGUBVSA-N Kuwanon H Natural products CC(C)=CCC1=C(O)C=CC(C(=O)[C@@H]2[C@@H](C=C(C)C[C@H]2C=2C(=CC(O)=CC=2)O)C=2C3=C(C(C(CC=C(C)C)=C(O3)C=3C(=CC(O)=CC=3)O)=O)C(O)=CC=2O)=C1O DKBPTKFKCCNXNH-YWUCGUBVSA-N 0.000 description 1
- FEAIYAOTVUYWQZ-QPFJYYDMSA-N Kuwanon K Natural products O=C([C@H]1[C@H](c2c(O)c(C3=C(C/C=C(\C)/C)C(=O)c4c(O)cc(O)cc4O3)ccc2O)C=C(C)C[C@@H]1c1c(O)cc(O)cc1)c1c(O)cc(O)cc1 FEAIYAOTVUYWQZ-QPFJYYDMSA-N 0.000 description 1
- QAFIXEVKRZHTEV-UHFFFAOYSA-N Kuwanon W Natural products OC1=CC(O)=C2C(=O)C(CC=C(C)C)=C(C=3C(=CC(O)=CC=3)O)OC2=C1C(C1C(=O)C=2C(=C3C=CC(C)(C)OC3=CC=2)O)C=C(C)CC1C1=CC=C(O)C=C1O QAFIXEVKRZHTEV-UHFFFAOYSA-N 0.000 description 1
- QAFIXEVKRZHTEV-AJKBGCORSA-N Kuwanon W Chemical compound C1([C@@H]2CC(C)=C[C@@H]([C@H]2C(=O)C=2C(=C3C=CC(C)(C)OC3=CC=2)O)C2=C3OC(=C(C(C3=C(O)C=C2O)=O)CC=C(C)C)C=2C(=CC(O)=CC=2)O)=CC=C(O)C=C1O QAFIXEVKRZHTEV-AJKBGCORSA-N 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- HMTMYIWMPJSCAZ-UHFFFAOYSA-N Moracin O Natural products O1C=2C=C3OC(C(C)(O)C)CC3=CC=2C=C1C1=CC(O)=CC(O)=C1 HMTMYIWMPJSCAZ-UHFFFAOYSA-N 0.000 description 1
- ZCFXYBGXLYJRGC-UHFFFAOYSA-N Moracin P Natural products CC(C)(CO)Oc1ccc2cc(oc2c1)c3cc(O)cc(O)c3 ZCFXYBGXLYJRGC-UHFFFAOYSA-N 0.000 description 1
- UWQYBLOHTQWSQD-UHFFFAOYSA-N Mulberrin Natural products CC(C)=CCC1=C(O)C=C(O)C(C(C=2CC=C(C)C)=O)=C1OC=2C1=CC=C(O)C=C1O UWQYBLOHTQWSQD-UHFFFAOYSA-N 0.000 description 1
- MSVXRBNAPJJEDX-UHFFFAOYSA-N Mulberrofuran Q Natural products C12=CC=C(O)C=C2OC(C)(C(C2C3=C(O)C=C(C=C3O3)C=4OC5=CC(O)=CC=C5C=4)=O)CC1C12OC13C1=CC=C(O)C=C1O MSVXRBNAPJJEDX-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 229930182734 Sanggenon Natural products 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- QNHQEUFMIKRNTB-UHFFFAOYSA-N aesculetin Natural products C1CC(=O)OC2=C1C=C(O)C(O)=C2 QNHQEUFMIKRNTB-UHFFFAOYSA-N 0.000 description 1
- GUAFOGOEJLSQBT-UHFFFAOYSA-N aesculetin dimethyl ether Natural products C1=CC(=O)OC2=C1C=C(OC)C(OC)=C2 GUAFOGOEJLSQBT-UHFFFAOYSA-N 0.000 description 1
- MJJWBJFYYRAYKU-OPKNDJPNSA-N albanol A Chemical compound C1([C@]23OC4=CC(O)=CC=C4[C@H]4[C@H]2[C@H](C2=C(O)C=C(C=C2O3)C=2OC3=CC(O)=CC=C3C=2)C=C(C4)C)=CC=C(O)C=C1O MJJWBJFYYRAYKU-OPKNDJPNSA-N 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- ILEDWLMCKZNDJK-UHFFFAOYSA-N esculetin Chemical compound C1=CC(=O)OC2=C1C=C(O)C(O)=C2 ILEDWLMCKZNDJK-UHFFFAOYSA-N 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- APPXYONGBIXGRO-UHFFFAOYSA-N kuwanon G Natural products OC1=CC(O)=C2C(=O)C(CC=C(C)C)=C(C=3C(=CC(O)=CC=3)O)OC2=C1C1C=C(C)CC(C=2C(=CC(O)=CC=2)O)C1C(=O)C1=CC=C(O)C=C1O APPXYONGBIXGRO-UHFFFAOYSA-N 0.000 description 1
- APPXYONGBIXGRO-AIQWNVMPSA-N kuwanone G Chemical compound O=C([C@H]1[C@@H](CC(C)=C[C@@H]1C1=C2OC(=C(C(C2=C(O)C=C1O)=O)CC=C(C)C)C=1C(=CC(O)=CC=1)O)C=1C(=CC(O)=CC=1)O)C1=CC=C(O)C=C1O APPXYONGBIXGRO-AIQWNVMPSA-N 0.000 description 1
- DKBPTKFKCCNXNH-QXGWMLRCSA-N kuwanone H Chemical compound CC(C)=CCC1=C(O)C=CC(C(=O)[C@@H]2[C@H](C=C(C)C[C@H]2C=2C(=CC(O)=CC=2)O)C=2C3=C(C(C(CC=C(C)C)=C(O3)C=3C(=CC(O)=CC=3)O)=O)C(O)=CC=2O)=C1O DKBPTKFKCCNXNH-QXGWMLRCSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- RTDFYRPWAYCBQQ-AZRHEHLBSA-N moracin M Natural products OC[C@H]1O[C@@H](Oc2ccc3C[C@H](Oc3c2)c4cc(O)cc(O)c4)[C@H](O)[C@@H](O)[C@@H]1O RTDFYRPWAYCBQQ-AZRHEHLBSA-N 0.000 description 1
- MJJWBJFYYRAYKU-UHFFFAOYSA-N mulberrofuran G Natural products C1C(C)=CC(C2=C(O)C=C(C=C2O2)C=3OC4=CC(O)=CC=C4C=3)C3C1C1=CC=C(O)C=C1OC32C1=CC=C(O)C=C1O MJJWBJFYYRAYKU-UHFFFAOYSA-N 0.000 description 1
- MSVXRBNAPJJEDX-PUGGFNCJSA-N mulberrofuran q Chemical compound C12([C@H]3CC(OC4=CC(O)=CC=C43)(C(C1C1=C(O)C=C(C=C1O1)C=3OC4=CC(O)=CC=C4C=3)=O)C)OC21C1=CC=C(O)C=C1O MSVXRBNAPJJEDX-PUGGFNCJSA-N 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- NKPFHPBRHZODPH-UHFFFAOYSA-N wittifuran V Natural products CC1(C)Oc2cc3cc(oc3cc2CC1O)c4cc(O)cc(O)c4 NKPFHPBRHZODPH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种从桑白皮中分离的新化合物及其制备方法和应用,涉及植物化学技术领域,新化合物化学结构式如下:
Description
技术领域
本发明涉及植物化学技术领域,尤其涉及一种从桑白皮中分离的新化合物及其制备方法和应用。
背景技术
桑白皮为桑科植物桑Morus alba L.的干燥根皮,主产于河南省、安徽省、四川省、湖南省、河北省、广东省。《中国药典》载:桑白皮性寒味甘,归肺经,用于泻肺平喘,利水消肿。桑白皮含有丰富化学成分,主要为黄酮类化合物、香豆素类、芪类化合物等成分,其中黄酮类化合物含量最多。
近年来科研人员从桑白皮中分离得到桑根皮醇(Morusinol)、桑皮酮H(KuwanonH)、Albanol B、桑根酮 G(Sanggenone G)、桑黄酮O(kuwanon O)、桑黄酮K(Kuwanon K)、桑辛素P(Moracin P)、草大戟素(Steppogenin)、桑辛素M(Moracin M)、桑辛素O(Moracin O)、3,5-二羟基苯甲醛(3,5-Dihydroxybenzaldehyde)、秦皮乙素(Esculetin)、5,7-二羟基香豆素(5,7-Dihydroxycoumarin)、白藜芦醇(Resveratrol)、香橙素(Aromadendrin)、桑呋喃G(Mulberrofuran G)、Albanin A、桑黄酮(Mulberrin)、Kuwanon W、桑黄酮G(Kuwanon G)、桑呋喃Q(Mulberrofuran Q)等系列特征性化合物,并开展了现代药理学研究。桑白皮具有多种药理作用,能够有效地缓解咳嗽和气喘等呼吸系统疾病的症状,促进痰液的排出,对于支气管炎、哮喘等疾病有一定的治疗作用;可以利尿,从而减轻水肿和高血压等疾病的症状;能够扩张血管,降低血压;抑制体内的炎症反应和疼痛传递,从而减轻关节炎、神经痛等疾病的疼痛和不适感;还可以抑制肿瘤细胞的生长和增殖。
本申请对桑白皮进行进一步的研究和开发,通过提取桑白皮中的有效成分,探索桑白皮在抗肿瘤方面的潜力,并寻求将其应用于肿瘤治疗的可能性,为临床提供更多治疗选择。
发明内容
为解决现有技术不足,本发明提供一种从桑白皮中分离的新化合物及其制备方法和应用,制备方法可以获得一种具有药理活性的新的药用化合物;该方法操作步骤简单,易于控制,整个生产流程耗时短。
为了实现本发明的目的,拟采用以下方案:
一种从桑白皮中分离的新化合物,化学结构式如下:
该化合物为白色固体,电喷雾电离质谱ESI-MS显示:正离子477.17[M+Na]+,负离子453.21[M-H]-,即该化合物分子量为454,分子式为C25H26O8,查阅文献,该化合物为一个新的化合物,自命名为桑根醇S(Sanggenol S)。
一种从桑白皮中分离的新化合物制备方法,包括以下步骤:
S1.将桑白皮粉碎,用50%-90%甲醇回流提取多次,过滤合并提取液,减压浓缩得浸膏a;将浸膏a用乙酸乙酯和水分散后,再用乙酸乙酯进行萃取多次,回收溶剂得乙酸乙酯萃取物;
S2.将乙酸乙酯萃取物用甲醇完全溶解,然后以萃取物质量的1倍-2倍硅胶为载体拌样,所得硅胶拌样物鼓风干燥后进行正相硅胶柱层析,以5倍-7倍硅胶为填料,湿法上样,用二氯甲烷-甲醇(100:0-0:1)溶剂体系为洗脱剂进行常压梯度洗脱,分段收集,根据薄层层析结果,将含有目标化合物的收集液合并,45℃-50℃减压浓缩干,得浸膏b;
S3.将浸膏b用甲醇溶解,再用滤膜过滤,滤液再经C18反相色谱系统制备分离,45℃-50℃减压浓缩,即得桑根醇S。
进一步的,步骤S1中,用50%甲醇回流提取3次,用乙酸乙酯进行萃取4次。
进一步的,步骤S2中,按萃取物质量的1.5倍硅胶拌样,正相硅胶柱层析时以6倍硅胶为填料。
进一步的,步骤S3中使用0.45μm滤膜过滤,45℃减压浓缩。
进一步的,步骤S3中使用的C18反相色谱系统,A:甲醇B:水,以A:B (55:45) V/V为流动相,检测波长288nm,收集对应的色谱峰。
进一步的,所得桑根醇S后,利用分析型液相色谱(RP-HPLC)复检产品纯度,测得结果98.90%以上。
一种从桑白皮中分离的新化合物的应用,在制备抗肿瘤药物中的应用,肿瘤包括肝癌、乳腺鳞状癌、宫颈癌、胃癌、肠癌、胶质瘤、白血病。
本发明的有益效果在于:以桑白皮为原料,经甲醇回流提取、乙酸乙酯萃取、硅胶柱层析分离、C18反相色谱系统制备等工艺步骤,可以获得一种具有药理活性的新的药用化合物;制备方法操作步骤简单,易于控制,整个生产流程耗时短。
具体实施方式
实施例1
S1.将桑白皮50kg粉碎用50%甲醇回流提取3次,过滤合并提取液,减压浓缩得浸膏a;将浸膏a用乙酸乙酯和水分散后,再用乙酸乙酯进行萃取4次,回收溶剂得乙酸乙酯萃取物,1.2kg。
S2.将乙酸乙酯萃取物用甲醇完全溶解,按其萃取物质量的1.5倍硅胶拌样,所得硅胶拌样物鼓风干燥后进行正相硅胶柱层析,以6倍的硅胶为填料,湿法上样,用二氯甲烷-甲醇(100:0-0:1)溶剂体系为洗脱剂进行常压梯度洗脱,分段收集,根据薄层层析结果,将含有目标化合物的收集液合并,于50℃减压浓缩至浸膏b,21g。
S3.将浸膏b用甲醇溶解,再用0.45μm滤膜过滤,滤液再经C18反相色谱系统制备分离,A:甲醇B:水,A:B (55:45) V/V为流动相,检测波长288nm,收集相对应的色谱峰,45℃减压浓缩,得到桑根醇S(Sanggenol S),50mg。
该化合物在整个生产流程中用时约5天。
利用分析型液相色谱(RP-HPLC)复检产品纯度,测得结果99.14%。
实施例2
S1.将桑白皮50kg粉碎用70%甲醇回流提取3次,过滤合并提取液,减压浓缩得浸膏a;将浸膏a用乙酸乙酯和水分散后,再用乙酸乙酯进行萃取4次,回收溶剂得乙酸乙酯萃取物,1.7kg。
S2.将乙酸乙酯萃取物用甲醇完全溶解,按其萃取物质量的1.5倍硅胶拌样,所得硅胶拌样物鼓风干燥后进行正相硅胶柱层析,以6倍的硅胶为填料,湿法上样,用二氯甲烷-甲醇(100:0-0:1)溶剂体系为洗脱剂进行常压洗脱,分段收集,根据薄层层析结果,将含有目标化合物的收集液合并,于50℃减压浓缩至浸膏b,33g。
S3.将浸膏b用甲醇溶解,再用0.45μm滤膜过滤,滤液再经C18反相色谱系统制备分离,A:甲醇B:水,A:B (55:45) V/V为流动相;检测波长288nm,收集相对应的色谱峰,45℃减压浓缩,得到桑根醇S(Sanggenol S),85mg。
该化合物在整个生产流程中用时约5天。
利用分析型液相色谱(RP-HPLC)复检产品纯度,测得结果98.90%。
实施例3
S1.将桑白皮50kg粉碎用90%甲醇回流提取3次,过滤合并提取液,减压浓缩得浸膏a;将浸膏a用乙酸乙酯和水分散后,再用乙酸乙酯进行萃取4次,回收溶剂得乙酸乙酯萃取物,2.5kg。
S2.将乙酸乙酯萃取物用甲醇完全溶解,按其萃取物质量的1.5倍硅胶拌样,所得硅胶拌样物鼓风干燥后进行正相硅胶柱层析,以6倍的硅胶为填料,湿法上样,用二氯甲烷-甲醇(100:0-0:1)溶剂体系为洗脱剂进行常压洗脱,分段收集,根据薄层层析结果,将含有目标化合物的收集液合并,于50℃减压浓缩至浸膏b,42g。
S3.将浸膏b用甲醇溶解,再用0.45μm滤膜过滤,滤液再经C18反相色谱系统制备分离,A:甲醇B:水,A:B (55:45) V/V为流动相;检测波长288nm,收集相对应的色谱峰,45℃减压浓缩,得到桑根醇S(Sanggenol S),130mg。
该化合物在整个生产流程中用时约5天。
利用分析型液相色谱(RP-HPLC)复检产品纯度,测得结果99.04%。
结构鉴定如下:
一种从桑白皮中分离的新化合物,化学结构式如下:
该化合物为白色固体,电喷雾电离质谱ESI-MS显示:正离子477.17[M+Na]+,负离子453.21[M-H]-,即该化合物分子量为454,分子式为C25H26O8,查阅文献,该化合物为一个新的化合物,自命名为桑根醇S(Sanggenol S)。
表1化合物数据归属(DMSO,TMS, δppm,J=Hz)
表1的H谱与C谱可以推断该化合物为二氢黄酮类化合物。
从氢谱上看,3个甲基取代基,δH 1.20,1.24,1.35 (eacH 3H, s);在低场部分显示有4个苯环的的质子信号δH5.89 (2H, s), 6.27 (1H, s), 7.51 (1H, s)。通过HSQC对其进行碳氢全归属,由HMBC发现δH 6.27 (H-2′)与δC 73.7 (C-2),116.5 (C-1′),123.5(C-9),153.2 (C-5′)相关;同时δH7.51(H-6′)与δC 73.7 (C-2),123.5 (C-4′),154.3 (C-2′),相关。除此之外,δH 3.77 (H-18)与δC132.0 (C-10),123.5 (C-9),69.4 (C-16),29.2(C-15)相关;结合NOESY,δH4.14(H-16-OH)与4.97(H-18-OH)相关,说明16、18位羟基构型为α。查阅文献,该化合物为一个新的化合物,自命名为桑根醇S(Sanggenol S)。
核磁共振HMBC和NOESY:
一种从桑白皮中分离的新化合物的应用,在制备抗肿瘤药物中的应用,肿瘤包括肝癌、乳腺鳞状癌、宫颈癌、胃癌、肠癌、胶质瘤、白血病。
桑根醇S(Sanggenol S)体外抗肿瘤活性试验:
采用MTT法,以顺铂为阳性对照药。取对数生长期的人肝癌HepG2细胞、人乳腺鳞状癌MCF-7细胞和HCC1086细胞、人宫颈癌H460细胞和A549细胞、人胃癌MGC-803细胞、人肠癌HCT116细胞、人胶质瘤SHG44细胞、人白血病CEM细胞,加无血清培养基调整细胞浓度为 5×104个/mL, 接种于96孔培养板,每孔200μL,37 ℃、5% CO2培养 12 小时,吸出培养基,取 20mg/mL WM-AC DMSO 溶液,加无血清培养基稀释后加新化合物和顺铂药物(6.25、12.5、25、50、100 μg/mL), 每个浓度设置 3 个复孔。继续培养 24 小时,吸出含药培养基,每孔加入无血清培养基 100 μL、5 mg/mL。取新化合物配置成(100、10、1、0.1、0.01、0.001 μg/mL)。
MTT溶液 20 μL,培养箱中孵育4 小时,弃去培养基,每孔加100 μL DMSO 充分震荡后,570 nm 处读取吸光度(A)值,所有化合物每个浓度均平行测试3次,计算被测药物对肿瘤细胞的抑制率。
采用非线性回归模型绘制S型剂量效应曲线,用OriginPro 软件计算半数抑制浓度(IC50)值。
抑制率=(A对照-A给药)/A对照
lgIC50=Xm-I[P-(3-Pm-Pn)/4]
Xm为lg最大剂量;I为 lg(最大剂量/相邻剂量);P为抑制率之和;Pm为最大抑制率;Pn为最小抑制率。
新化合物桑根醇S(Sanggenol S)的体外抗肿瘤活性结果见表2,根据试验结果可以看到,新化合物桑根醇S(Sanggenol S)对人肝癌HepG2细胞、人乳腺鳞状癌MCF-7细胞和HCC1086细胞、人宫颈癌H460细胞和A549细胞、人胃癌MGC-803细胞、人肠癌HCT116细胞、人胶质瘤SHG44细胞、人白血病CEM细胞的均表现出较强的抑制作用,其中对人胃癌MGC-803细胞和人胶质瘤SHG44细胞的抑制效果强于阳性药顺铂。
表2桑根醇S对肿瘤细胞的抑制作用
以上实施例仅用于说明本发明的技术思想及特点,并不表示是唯一的或是限制本发明。本领域技术人员应理解,在不脱离本发明的范围情况下,对本发明进行的各种改变或同等替换,均属于本发明保护的范围。
Claims (9)
1.一种从桑白皮中分离的新化合物,其特征在于,该化合物分子量为454,分子式为C25H26O8,自命名为桑根醇S(Sanggenol S),化学结构式如下:
。
2.根据权利要求1所述的从桑白皮中分离的新化合物,其特征在于,白色固体,电喷雾电离质谱ESI-MS显示:正离子477.17[M+Na]+,负离子453.21[M-H]-。
3.一种如权利要求1或2所述的从桑白皮中分离的新化合物制备方法,其特征在于,包括以下步骤:
S1.将桑白皮粉碎,用50%-90%甲醇回流提取多次,过滤合并提取液,减压浓缩得浸膏a;将浸膏a用乙酸乙酯和水分散后,再用乙酸乙酯进行萃取多次,回收溶剂得乙酸乙酯萃取物;
S2.将乙酸乙酯萃取物用甲醇完全溶解,然后以萃取物质量的1倍-2倍硅胶为载体拌样,所得硅胶拌样物鼓风干燥后进行正相硅胶柱层析,以5倍-7倍硅胶为填料,湿法上样,用二氯甲烷-甲醇(100:0-0:1)溶剂体系为洗脱剂进行常压梯度洗脱,分段收集,根据薄层层析结果,将含有目标化合物的收集液合并,45℃-50℃减压浓缩干,得浸膏b;
S3.将浸膏b用甲醇溶解,再用滤膜过滤,滤液再经C18反相色谱系统制备分离,45℃-50℃减压浓缩,即得桑根醇S。
4.根据权利要求3所述的制备方法,其特征在于,步骤S1中,用50%甲醇回流提取3次,用乙酸乙酯进行萃取4次。
5.根据权利要求3所述的制备方法,其特征在于,步骤S2中,按萃取物质量的1.5倍硅胶拌样,正相硅胶柱层析时以6倍硅胶为填料。
6.根据权利要求3所述的制备方法,其特征在于,步骤S3中使用0.45μm滤膜过滤,45℃减压浓缩。
7.根据权利要求3所述的制备方法,其特征在于,步骤S3中使用的C18反相色谱系统,A:甲醇B:水,以A:B (55:45) V/V为流动相,检测波长288nm,收集对应的色谱峰。
8.根据权利要求3所述的制备方法,其特征在于,所得桑根醇S后,利用分析型液相色谱(RP-HPLC)复检产品纯度,测得结果98.90%以上。
9.一种如权利要求1或2所述的从桑白皮中分离的新化合物的应用,其特征在于,在制备抗肿瘤药物中的应用,肿瘤包括肝癌、乳腺鳞状癌、宫颈癌、胃癌、肠癌、胶质瘤、白血病任意一种或多种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310764253.5A CN116751179A (zh) | 2023-06-27 | 2023-06-27 | 一种从桑白皮中分离的新化合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310764253.5A CN116751179A (zh) | 2023-06-27 | 2023-06-27 | 一种从桑白皮中分离的新化合物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116751179A true CN116751179A (zh) | 2023-09-15 |
Family
ID=87960652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310764253.5A Pending CN116751179A (zh) | 2023-06-27 | 2023-06-27 | 一种从桑白皮中分离的新化合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116751179A (zh) |
-
2023
- 2023-06-27 CN CN202310764253.5A patent/CN116751179A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112094176A (zh) | 一种从山橿中提取的二苯乙烯类化合物及其制备方法与应用 | |
CN114835668B (zh) | 青龙衣中一种环醚型二芳基庚烷的制备方法和应用 | |
CN116751179A (zh) | 一种从桑白皮中分离的新化合物及其制备方法和应用 | |
CN112920151B (zh) | 异戊烯基黄酮类化合物及其制备方法和应用 | |
CN113754620B (zh) | 火麻仁中的木脂素酰胺类化合物及其制备方法和应用 | |
CN113620912B (zh) | 一种呋喃酮化合物及其制备方法与应用 | |
CN112194645B (zh) | 一种新化合物及其在抑制黑色素瘤方面的用途 | |
CN111253352B (zh) | 一种从中药斑叶兰中提取分离的化合物及其制备方法和应用 | |
CN111499605B (zh) | 一种异戊烯基色原酮类化合物及其制备方法和应用 | |
CN108250207B (zh) | 一种香豆素类化合物及其制备方法和应用 | |
CN109206392B (zh) | 一种香豆素类化合物及其制备方法与应用 | |
CN116789657B (zh) | 一种具有抗炎活性的化合物及其提取分离方法和应用 | |
CN111606801A (zh) | 一种裂环半日花烷型二萜类化合物及其分离方法和应用 | |
CN114031625B (zh) | 甘草中具有抗结直肠癌活性的化合物制备及其应用 | |
CN114621129B (zh) | 抗肿瘤化合物及其制备方法和用途 | |
CN110642821B (zh) | 酢浆草中一种化合物及其提取分离方法及应用 | |
CN115385924B (zh) | 一种具有抗肿瘤活性的环戊烷苯并呋喃类化合物及其应用 | |
CN114835568B (zh) | 核桃青皮中一种联苯型二芳基庚烷的制备方法和应用 | |
CN109180696B (zh) | 环烯酮类化合物及其制备方法和应用 | |
CN111995647B (zh) | 从绿萼梅中分离的具有抗肿瘤活性的化合物及其制备方法 | |
CN111454241B (zh) | 双异戊烯基黄酮类化合物及其制备方法和应用 | |
CN112778255B (zh) | 鹅不食草内酯l及提取方法及其用途 | |
CN111892567B (zh) | 一种从山橿中提取的二氢黄酮类化合物及其制备方法与应用 | |
CN106967026A (zh) | 当归中香豆素1的制备方法和应用 | |
CN108530505A (zh) | 一种黄酮苷类化合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |